本帖最后由 老马 于 2012-1-13 21:20 编辑 - T6 x/ F) J B6 p7 d$ ?
& o4 a+ m7 |! @爱必妥和阿瓦斯丁的比较
. w6 `2 j2 }" R; ^4 m
" o$ x- w3 v3 T! g f( ~0 H1 `) I5 [http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
/ w) \ D6 R4 j7 |' b9 k, h
8 A/ [( `) E* W! E$ `4 r4 y
. g6 ]% u! R2 z% P# L3 X" nhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
4 y1 W- N, i/ H: X# p==================================================
. T1 `0 C |6 }8 k4 M& `" N; cOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
6 A* O- {0 N- xPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.: U9 @, p! f6 m, M* \* p( X1 `- a
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.; F0 U' d, a6 ]7 @- O2 Q& c
|